Follow
Giuseppe (Nello) Ambrosio
Giuseppe (Nello) Ambrosio
Cardiology, University of Perugia School of Medicine
Verified email at unipg.it
Title
Cited by
Cited by
Year
Telmisartan, ramipril, or both in patients at high risk for vascular events
PJ Yusuf S, Teo KK
New England Journal of Medicine 358, 1547-59, 2008
4951*2008
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
S BM
New England Journal of Medicine 369, 1317, 2013
42442013
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
JB Green, MA Bethel, PW Armstrong, JB Buse, SS Engel, J Garg, R Josse, ...
New England Journal of Medicine 373 (3), 232-242, 2015
31652015
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
FG Anker Stefan D, Butler J
N Engl J Med 385, 2021
3139*2021
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine
NEW ENGLAND JOURNAL OF MEDICINE 352, 1179, 2005
29182005
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
HAF Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan ...
N Engl J Med 377 (13), 1228-1239, 2017
2011*2017
Bivalirudin for patients with acute coronary syndromes
GW Stone, BT McLaurin, DA Cox, ME Bertrand, AM Lincoff, JW Moses, ...
New England Journal of Medicine 355 (21), 2203-2216, 2006
17522006
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
FR Fox K, Ford I, Steg PG, Tendera M, B Investigators.
Lancet 372, 807, 2008
14772008
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised …
TK Yusuf S
Lancet 372, 1174-83, 2008
12322008
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
MT Roe
New England Journal of Medicine, 2012
10912012
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
A PW
New England Journal of Medicine 382, 1883-1893, 2020
10812020
Microcirculation in Hypertension A New Target for Treatment?
BI Levy, G Ambrosio, AR Pries, HAJ Struijker-Boudier
Circulation 104 (6), 735-740, 2001
9642001
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
P Tricoci, Z Huang, C Held, DJ Moliterno, PW Armstrong, F Van de Werf, ...
New England Journal of Medicine 366 (1), 20-33, 2012
9062012
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term …
O Chioncel, M Lainscak, PM Seferovic, SD Anker, MG Crespo‐Leiro, ...
European journal of heart failure 19 (12), 1574-1585, 2017
9002017
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
M Konstam
Lancet 374, 1840, 2009
8052009
From endothelial dysfunction to atherosclerosis
S Sitia, L Tomasoni, F Atzeni, G Ambrosio, C Cordiano, A Catapano, ...
Autoimmunity reviews 9 (12), 830-834, 2010
7532010
Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow.
G Ambrosio, JL Zweier, C Duilio, P Kuppusamy, G Santoro, PP Elia, ...
Journal of Biological Chemistry 268 (25), 18532-18541, 1993
6561993
Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow.
G Ambrosio, HF Weisman, JA Mannisi, LC Becker
Circulation 80 (6), 1846-1861, 1989
6271989
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Teerlink JR
N Engl J Med 384, 105-116, 2021
5492021
Reperfusion injury: experimental evidence and clinical implications
G Ambrosio, I Tritto
American heart journal 138 (2), S69-S75, 1999
4921999
The system can't perform the operation now. Try again later.
Articles 1–20